Focused On-demand Library for Interleukin-18 receptor accessory protein

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
O95256

UPID:
I18RA_HUMAN

ALTERNATIVE NAMES:
Accessory protein-like; CD218 antigen-like family member B; CDw218b; IL-1R accessory protein-like; Interleukin-1 receptor 7; Interleukin-18 receptor accessory protein-like; Interleukin-18 receptor beta

ALTERNATIVE UPACC:
O95256; B2RPJ3; Q2QDE5; Q3KPE7; Q3KPE8; Q53TT4; Q53TU5

BACKGROUND:
Interleukin-18 receptor accessory protein, also referred to as CD218 antigen-like family member B and Interleukin-1 receptor 7, is integral to the IL18 signaling pathway. It does not bind IL18 directly but is essential for IL18-mediated signal transduction leading to the activation of critical transcription factors. Its role in promoting IFNG production from Th1 cells underscores its importance in immune regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Interleukin-18 receptor accessory protein offers promising avenues for the development of novel therapeutic interventions. Its pivotal role in immune signaling pathways makes it a potential target for therapeutic strategies aimed at enhancing or suppressing immune responses.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.